The most important and reliable changes observed in platelets from AD patients are reduced APP ratio, alteration of α- and β-secretase expression or activity that result in abnormal APP metabolism through the amyloidogenic pathway, and enhanced platelet activation. Here, APP is linked to Alzheimer disease.